Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 8/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | TKT | P29401 | 2/20 | 0.40 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29680366 | 0.82 | — | — | |
| SCHEMBL318613 | 0.82 | — | — | |
| SCHEMBL2384178 | 0.81 | BACE1 (0.51) | BACE1NOS3NOS1NOS2KDM1A | |
| SCHEMBL317901 | 0.81 | BACE1 (0.51) | BACE1NOS3NOS1NOS2KDM1A | |
| SCHEMBL4618729 | 0.81 | TKT (0.52) | BACE1NOS3NOS1NOS2KDM1A | |
| Hydrochloric Acid SCHEMBL14354440 | 0.80 | NOS3 (0.46) | BACE1NOS3NOS1NOS2DPP4 | |
| SCHEMBL28126688 | 0.78 | HRH1 (0.47) | HRH1TAAR1HTR2ACHRNA7DPP4 | |
| SCHEMBL11390568 | 0.78 | HRH1 (0.42) | BACE1HRH1TAAR1NOS3NOS1 | |
| SCHEMBL8049756 | 0.78 | BACE1 (0.49) | BACE1NOS3NOS1NOS2TKT | |
| SCHEMBL6834581 | 0.78 | BACE1 (0.49) | BACE1NOS3NOS1NOS2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101495464-B | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA NV | 2014-03-05 | — | — | CN | claimed |
| CN-103396398-A | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA NV | 2013-11-20 | — | — | CN | claimed |
| EP-2585069-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | Janssen Pharmaceutica, N.V. (BE) | 2013-05-01 | — | — | EP | claimed |
| EP-1973886-B1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-27 | — | — | EP | claimed |
| US-8372973-B2 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-12 | — | — | US | claimed |
| US-20120028997-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | COATS STEVEN J (US) | 2012-02-02 | — | — | US | claimed |
| WO-2012006004-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-12 | — | — | WO | claimed |
| US-20110319400-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA, NV (BE) | 2011-12-29 | — | — | US | claimed |
| EP-2385042-A1 | Prokineticin 1 receptor antagonists | Janssen Pharmaceutica N.V. (BE) | 2011-11-09 | — | — | EP | claimed |
| US-8039028-B2 | Use of an extract of the orchid Vanda coerulea as a skin hydrating agent | LVMH REACHERCHE (FR) | 2011-10-18 | — | — | US | claimed |
| US-7902358-B2 | Gastrointestinal disorders; inflammatory bowel disorders; gastroesophageal reflux, constipation; diarrhea | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-08 | — | — | US | claimed |
| CN-101495464-A | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-29 | — | — | CN | claimed |
| CN-101405002-A | Prokineticin 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-08 | — | — | CN | claimed |
| US-20080287445-A1 | Prokineticin 2 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-20 | — | — | US | claimed |
| US-20080269225-A1 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-30 | — | — | US | claimed |
| EP-1976528-A2 | PROKINETICIN 2 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-10-08 | — | — | EP | claimed |
| EP-1973886-A2 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-10-01 | — | — | EP | claimed |
| WO-2007079214-A2 | PROKINETICIN 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | claimed |
| WO-2007079163-A2 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | claimed |
| WO-2025151594-A1 | FUSED AZINES AS RAS INHIBITORS AND METHODS OF USE THEREOF | KESTREL THERAPEUTICS INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| WO-2025122956-A1 | COMBINATION THERAPY | VIVACE THERAPEUTICS, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| WO-2025034563-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | VIVACE THERAPEUTICS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| WO-2024259169-A1 | PYRIMIDINE BASED MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| EP-3877356-A1 | BICYCLIC COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2021-09-15 | — | — | EP | disclosed |
| EP-2385042-B1 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-25 | — | — | EP | disclosed |
| CN-101495464-B | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA NV | 2014-03-05 | — | — | CN | disclosed |
| CN-103396398-A | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA NV | 2013-11-20 | — | — | CN | disclosed |
| EP-2585069-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | Janssen Pharmaceutica, N.V. (BE) | 2013-05-01 | — | — | EP | disclosed |
| EP-1973886-B1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-27 | — | — | EP | disclosed |
| US-8372973-B2 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-12 | — | — | US | disclosed |
| US-20120028997-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | COATS STEVEN J (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2012006004-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-12 | — | — | WO | disclosed |
| US-20110319400-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA, NV (BE) | 2011-12-29 | — | — | US | disclosed |
| EP-2385042-A1 | Prokineticin 1 receptor antagonists | Janssen Pharmaceutica N.V. (BE) | 2011-11-09 | — | — | EP | disclosed |
| US-8039028-B2 | Use of an extract of the orchid Vanda coerulea as a skin hydrating agent | LVMH REACHERCHE (FR) | 2011-10-18 | — | — | US | disclosed |
| US-7902358-B2 | Gastrointestinal disorders; inflammatory bowel disorders; gastroesophageal reflux, constipation; diarrhea | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-08 | — | — | US | disclosed |
| EP-1641423-B1 | BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2010-03-17 | — | — | EP | disclosed |
| CN-101495464-A | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-29 | — | — | CN | disclosed |
| CN-101405002-A | Prokineticin 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-08 | — | — | CN | disclosed |
| US-7476665-B2 | Benzodiazepine CGRP receptor antagonists | MERCK & CO., INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-20080287445-A1 | Prokineticin 2 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-20 | — | — | US | disclosed |
| US-20080269225-A1 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-30 | — | — | US | disclosed |
| EP-1976528-A2 | PROKINETICIN 2 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-10-08 | — | — | EP | disclosed |
| EP-1973886-A2 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-10-01 | — | — | EP | disclosed |
| EP-1641423-A4 | BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007079214-A2 | PROKINETICIN 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007079163-A2 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | disclosed |
| US-20070111204-A1 | Methods for detecting nucleic acid variations | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE | 2007-05-17 | — | — | US | disclosed |
| CN-1842526-A | Benzodiazepine CGRP receptor antagonists | MERCK & CO INC (US) | 2006-10-04 | — | — | CN | disclosed |
| US-20060135511-A1 | Benzodiazepine cgrp receptor antagonists | MERCK SHARP & DOHME LLC | 2006-06-22 | — | — | US | disclosed |
| EP-1641423-A2 | BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005013894-A2 | BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| EP-0528854-B1 | FLUOROGENIC PEPTIDES AND THEIR USE IN THE DETERMINATION OF ENZYMATIC ACTIVITIES | CARLSBERG AS (DK) | 1994-12-28 | — | — | EP | disclosed |
| EP-0528854-A1 | FLUOROGENIC PEPTIDES AND THEIR USE IN THE DETERMINATION OF ENZYMATIC ACTIVITIES. | CARLSBERG AS (DK) | 1993-03-03 | — | — | EP | disclosed |
| WO-1991016336-A1 | FLUOROGENIC PEPTIDES AND THEIR USE IN THE DETERMINATION OF ENZYMATIC ACTIVITIES | CARLSBERG A/S (DK) | 1991-10-31 | — | — | WO | disclosed |
| WO-1991016336-A1 | FLUOROGENIC PEPTIDES AND THEIR USE IN THE DETERMINATION OF ENZYMATIC ACTIVITIES | CARLSBERG A/S (DK) | 1991-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028997-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | PROKR1, PROKR2, GIPR | BACE1 2940/4885HRH1 167/4885TAAR1 330/4885 |
| US-20060135511-A1 | Benzodiazepine cgrp receptor antagonists | NPY1R, NPY2R, CCKBR | BACE1 681/4885HRH1 76/4885TAAR1 198/4885 |
| US-20110319400-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | PROKR1, OPRL1, PROKR2 | BACE1 2220/4885HRH1 55/4885TAAR1 244/4885 |
| US-20070111204-A1 | Methods for detecting nucleic acid variations | POLN, LIG4, NCL | BACE1 4608/4885HRH1 4400/4885TAAR1 2383/4885 |
| US-20080269225-A1 | Prokineticin 1 receptor antagonists | PROKR1, PROKR2, GIPR | BACE1 2940/4885HRH1 167/4885TAAR1 330/4885 |
| US-20080287445-A1 | Prokineticin 2 receptor antagonists | PROKR2, PROKR1, GIPR | BACE1 4016/4885HRH1 198/4885TAAR1 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.